All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Miltenyi Biomedicine, Nurix Therapeutics, Roche, Sobi, and Thermo Fisher Scientific and supported through educational grants from Bristol Myers Squibb, Lilly, and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Visual abstract | Phase I/II BGB-11417-201 trial primary analysis: Sonrotoclax monotherapy in R/R MCL
Do you know... Sonrotoclax is being assessed in the phase I/II BGB-11417-201 trial for the treatment of R/R MCL. Which mechanism of action best describes sonrotoclax?
Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) with disease progression during or following treatment with Bruton’s tyrosine kinase inhibitors (BTKi) have limited treatment options.1 Sonrotoclax, a next-generation B-cell lymphoma-2 inhibitor (BCL-2i), has recently been granted breakthrough therapy designation and priority review by the U.S. Food and Drug Administration (FDA) for the treatment of R/R MCL.2,3 The ongoing, multicenter, single-arm, open-label, phase I/II BGB-11417-201 trial (NCT05471843) is assessing the efficacy and safety of sonrotoclax in 125 adult patients with R/R MCL previously treated with a BTKi.1
Results from the BGB-11417-201 trial were presented by Michael Wang during the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, and are summarized below.1
This educational resource is independently supported by BeOne Medicines. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
